Mirna Therapeutics (NASDAQ: SYBX) and Cardiome Pharma Corporation (NASDAQ:CRME) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.


This table compares Mirna Therapeutics and Cardiome Pharma Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mirna Therapeutics N/A -44.70% -42.29%
Cardiome Pharma Corporation -110.95% -78.51% -38.30%

Risk & Volatility

Mirna Therapeutics has a beta of 3.73, indicating that its share price is 273% more volatile than the S&P 500. Comparatively, Cardiome Pharma Corporation has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Institutional & Insider Ownership

55.1% of Cardiome Pharma Corporation shares are held by institutional investors. 18.6% of Mirna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Mirna Therapeutics and Cardiome Pharma Corporation’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Mirna Therapeutics N/A N/A -$26.26 million ($9.59) -1.16
Cardiome Pharma Corporation $25.26 million 1.94 -$19.61 million ($0.82) -1.77

Cardiome Pharma Corporation has higher revenue and earnings than Mirna Therapeutics. Cardiome Pharma Corporation is trading at a lower price-to-earnings ratio than Mirna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Mirna Therapeutics and Cardiome Pharma Corporation, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirna Therapeutics 0 2 1 0 2.33
Cardiome Pharma Corporation 0 0 3 0 3.00

Mirna Therapeutics currently has a consensus price target of $19.50, suggesting a potential upside of 75.68%. Cardiome Pharma Corporation has a consensus price target of $7.58, suggesting a potential upside of 422.99%. Given Cardiome Pharma Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe Cardiome Pharma Corporation is more favorable than Mirna Therapeutics.


Cardiome Pharma Corporation beats Mirna Therapeutics on 8 of the 12 factors compared between the two stocks.

About Mirna Therapeutics

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

About Cardiome Pharma Corporation

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Receive News & Stock Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related stocks with our FREE daily email newsletter.